Key points
- Actinogen Medical Ltd signs underwriting agreement for unlisted options with Forrest Capital
- Agreement ensures Actinogen receives approximately $4.77 million in funding
- Funding to support the company through pivotal Alzheimer's disease trial results
- Underwriting agreement provides certainty until late CY2027 or early CY2028
- Forrest Capital, a long-term shareholder, endorses the potential of Actinogen's drug Xanamem
Full summary
Actinogen Medical Ltd (ACW) announced the signing of an underwriting agreement with Forrest Capital for two tranches of unlisted options, ensuring the company will receive approximately $4.77 million in funding. This agreement provides certainty for Actinogen until late CY2027 or early CY2028. The company is entering a transformative period with pivotal trial results for its Alzheimer's disease drug, Xanamem, expected in November. The underwriting agreement covers all outstanding options, providing a financial runway beyond the trial results. Forrest Capital, a long-term shareholder, views this underwriting as an endorsement of Xanamem's potential.
Guidance
Approximately $4.77 million additional funding from underwriting agreement
Outlook
The company expects to receive the full value of unexercised options by late CY2027 or early CY2028, ensuring a secure cash runway.